Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2014

01-04-2014 | Commentary

Omalizumab: Stepping Outside Our Comfort Zone to Broaden the Number of Those Who Can Benefit

Authors: Mario Cazzola, Andrea Segreti

Published in: Drugs | Issue 5/2014

Login to get access

Excerpt

An increasing body of evidence indicates that omalizumab, a recombinant humanised IgG1 non-complement-fixing monoclonal antibody that binds to the high-affinity receptor-binding domain (Cε3) on the Fc portion of free IgE, is clinically effective in patients with intrinsic asthma [1‐3], which, by definition, is asthma without atopy and, consequently, without clinical or serological evidence of IgE-mediated allergy to common environmental agents [4], and also in other morbid conditions not associated with IgE [5]. This evidence is surprising because IgE represents the substrate on which omalizumab acts. However, the possibility of also using omalizumab in non-atopic patients is extremely exciting because about one-third of adult asthmatic patients are non-atopic, and these patients usually have more severe and difficult-to-control disease [6]. …
Literature
1.
de Llano LP, Vennera Mdel C, Alvarez FJ, et al. Effects of omalizumab in non-atopic asthma: results from a spanish multicenter registry. J Asthma. 2013;50:296–301.
2.
Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110–6.PubMedCrossRef
3.
Garcia G, Magnan A, Chiron R, et al. A proof of concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma. Chest. 2013;144(2):411–9.PubMedCrossRef
4.
Humbert M, Menz G, Ying S, Corrigan CJ, Robinson DS, Durham SR, Kay AB. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today. 1999;20(11):528–33.PubMedCrossRef
5.
Babu KS, Polosa R, Morjaria JB. Anti-IgE-emerging opportunities for omalizumab. Expert Opin Biol Ther. 2013;13:765–77.PubMedCrossRef
6.
Dullaers M, De Bruyne R, Ramadani F, Gould HJ, Gevaert P, Lambrecht BN. The who, where, and when of IgE in allergic airway disease. J Allergy Clin Immunol. 2012;129(3):635–45.PubMedCrossRef
7.
8.
Buhl R, Marco AG, Cohen D, Canonica GW. Eligibility for treatment with omalizumab in Italy and Germany. Respir Med. 2014;108(1):50-6.
9.
10.
Domingo C. Omalizumab for severe asthma: efficacy beyond the atopic patient? Drugs. 2014.
11.
12.
Humbert M, Menz G, Ying S, Corrigan CJ, Robinson DS, Durham SR, Kay AB. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today. 1999;20(11):528–33.PubMedCrossRef
13.
14.
15.
Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–6.e1.
16.
Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S, et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010;126:962–8, 968.e1–6.
17.
Sanchez J, Ramirez R, Diez S, Sus S, Echenique A, Olivares M, Cardona R. Omalizumab beyond asthma. Allergol Immunopathol (Madr). 2012;40(5):306–15.PubMedCrossRef
18.
Chanez P, Contin-Bordes C, Garcia G, Verkindre C, Didier A, De Blay F, de Lara MT, Blanco P, Moreau JF, Robinson P, Bourdeix I, Trunet P, Le Gros V, Humbert M, Molimard M. Omalizumab-induced decrease of FcεRI expression in patients with severe allergic asthma. Respir Med. 2010;104(11):1608–17.PubMedCrossRef
19.
Korn S, Haasler I, Fliedner F, et al. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med. 2012;106:1494–500.PubMedCrossRef
20.
Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–11.PubMedCrossRef
21.
Chung KF. New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respir Med. 2013;1:639–52.PubMedCrossRef
22.
Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, ten Brinke A, Bel EH. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol. 2013;132:336–41.PubMedCrossRef
23.
Amelink M, de Nijs SB, de Groot JC, van Tilburg PM, van Spiegel PI, Krouwels FH, Lutter R, Zwinderman AH, Weersink EJ, ten Brinke A, Sterk PJ, Bel EH. Three phenotypes of adult-onset asthma. Allergy. 2013;68(5):674–80.PubMedCrossRef
24.
Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, Nagai H, Hotokebuchi T, Izuhara K. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118:98–104.PubMedCrossRef
Metadata
Title
Omalizumab: Stepping Outside Our Comfort Zone to Broaden the Number of Those Who Can Benefit
Authors
Mario Cazzola
Andrea Segreti
Publication date
01-04-2014
Publisher
Springer International Publishing
Published in
Drugs / Issue 5/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0205-9

Other articles of this Issue 5/2014

Drugs 5/2014 Go to the issue

Current Opinion

Omalizumab for Severe Asthma: Efficacy Beyond the Atopic Patient?

Adis Drug Evaluation

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis

Current Opinion

Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis

Systematic Review

Meta-Review: Adverse Effects of Inhaled Corticosteroids Relevant to Older Patients

Adis Drug Evaluation

Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma

Adis Drug Evaluation

Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus